Profile: Osiris Therapeutics Inc (OSIR.OQ)
21 Nov 2014
Osiris Therapeutics, Inc. (Osiris), incorporated on March 30, 2010, is a stem cell company. The Company is an integrated company, having developed capabilities in research, development, manufacturing, marketing and distribution of stem cell products. The Company has developed an intellectual property portfolio to protect its technology and commercial interests. Its Biosurgery business works to harness the ability of cells and constructs to promote the body's natural healing with the goals of improving surgical outcomes and offering better treatment options for patients and physicians. The Company’s Biosurgery products includes Grafix, Ovation, Cartiform, and OvationOS, each of which it developed and manufacture.
Grafix is a three-dimensional placental tissue matrix for use as a wound covering for application directly to acute and chronic wounds, including diabetic foot ulcers, venous leg ulcers, and burns. OvationOS is a viable bone matrix, is its newest product to be used for bone repair and regeneration. It is a cancellous bony matrix containing viable endogenous MSCs and osteoprogenitor cells. It contains components for bone regeneration, including structural biologic matrix, reservoir of growth factors and endogenous MSCs. OvationOS is a functionally complete alternative to autograft, the gold standard in bone regeneration. Cartiform is viable cartilage mesh designed for use in cartilage repair, such as marrow stimulation procedures. Cartiform maintains a type II collagen architecture and functioning chondrocytes to preserve the natural properties of hyaline cartilage and recruit the patient's MSCs for improved chondrogenesis.
Osiris Therapeutics Inc
7015 Albert Einstein Drive
COLUMBIA MD 21046